![{[setting('site_name')]}](https://flipnews.ca/uploads/setting/1694688257236407702.jpg)
- Genetic testing firm 23andMe is reducing its workforce by 40%, affecting around 200 employees.
- The company is discontinuing further development of its therapy programs as part of a restructuring effort.
- CEO Anne Wojcicki stated that these actions are necessary to focus on the core consumer business and research partnerships.
23andMe Cuts 40% of Workforce, Discontinues Therapy Programs
Share
